Epigral Ltd (EPIGRAL) — shareholding pattern, promoter holding, financials and share price
About Epigral Ltd (EPIGRAL)
Epigral Ltd operates in the Specialty Chemicals industry, within the Chemicals sector. It trades on the NSE as EPIGRAL and on the BSE under scrip code 543332. Its ISIN is INE071N01016.
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals. [1]
Epigral Limited, formerly Meghmani Finechem Limited, is a prominent player in India's chlor alkali industry, involved in manufacturing chlor alkali products and derivatives, along with trading agrochemicals.
The company has recently finalized capex plans aiming to double the capacity of its CPVC and epichlorohydrin plants, hinting at a robust strategic expansion.
Listed peers in Specialty Chemicals: Fineotex Chemical Ltd, Laxmi Organic Industries Ltd, Vishnu Chemicals Ltd, Styrenix Performance Materials Ltd, Foseco India Ltd, Yasho Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹987.4 a share on 10 Jul 2026, Epigral Ltd (EPIGRAL) was valued at a price-to-earnings ratio of 12.83x against an industry P/E of 45.11x and a price-to-book of 1.92x on a book value of ₹514.92 per share as of Mar 2026. Solomo computes return on equity of 14.94% and return on capital employed of 14.77% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 12.83x
- Industry P/E
- 45.11x
- P/B
- 1.92x
- EPS (TTM)
- ₹76.95
- Book value / share
- ₹514.92
- ROE
- 14.94%
- ROCE
- 14.77%
- ROA
- 9.47%
- Debt / equity
- 0.26x
- Dividend yield
- 0.51%
- EBITDA margin
- 22.99%
- 52-week range
- ₹806.2 – ₹2,114.3
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Epigral Ltd (EPIGRAL) reported revenue of ₹2,527 crore, net profit of ₹332 crore and earnings per share of ₹76.95. That compares with revenue of ₹2,550 crore and net profit of ₹358 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹736 crore and net profit ₹81 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,551 | 2,188 | 1,929 | 2,550 | 2,527 |
| Net profit (₹ cr) | 253 | 353 | 196 | 358 | 332 |
| EPS (₹) | 60.84 | 85.03 | 47.14 | 82.91 | 76.95 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 21.31% | 24.99% | 4.91% | -0.90% |
| Profit growth | 19.59% | 26.99% | -1.96% | -7.19% |
| Stock price CAGR | - | - | 2% | -40% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.83% of Epigral Ltd (EPIGRAL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.03% and domestic institutional investors (DII) hold 5.56%. Market capitalisation was ₹4,260 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.
Largest disclosed public shareholders in Jun 2026: Bandhan Small Cap Fund 2.95%, HSBC Mutual Fund - HSBC Value Fund 2.56%, VLS Finance Ltd 1.91%, HUF 1.29%, LLP 1.03%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.83% | - | 1.03% | 5.56% | 31.17% |
| Mar 2026 | 68.83% | - | 1.54% | 4.9% | 31.17% |
| Dec 2025 | 68.83% | - | 2.36% | 5.13% | 31.17% |
| Sep 2025 | 68.83% | - | 2.71% | 4.92% | 31.17% |
| Jun 2025 | 68.83% | - | 3.05% | 4.79% | 31.17% |
| Mar 2025 | 68.95% | - | 3.01% | 4.66% | 31.05% |
| Dec 2024 | 68.94% | - | 3.01% | 4.31% | 31.06% |
| Sep 2024 | 71.58% | - | 2.09% | 1.17% | 28.42% |